STRIDES PHARMA SCIENCE Financial Statement Analysis
|
||
|
The Revenues of STRIDES PHARMA SCIENCE have increased by 9.83% YoY .
The Earnings Per Share (EPS) of STRIDES PHARMA SCIENCE has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
STRIDES PHARMA SCIENCE Last 5 Annual Financial Results
[BOM: 532531|NSE : STAR]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹4,051 Cr | ₹3,688 Cr | ₹3,070 Cr | ₹3,316 Cr | ₹2,752 Cr |
| Expenses | ₹3,318 Cr | ₹3,303 Cr | ₹3,092 Cr | ₹2,689 Cr | ₹2,236 Cr |
| Operating Profit (Excl OI) | ₹733 Cr | ₹385 Cr | ₹-22 Cr | ₹627 Cr | ₹516 Cr |
| Other Income | ₹50 Cr | ₹135 Cr | ₹133 Cr | ₹59 Cr | ₹53 Cr |
| Interest | ₹314 Cr | ₹261 Cr | ₹177 Cr | ₹150 Cr | ₹156 Cr |
| Depreciation | ₹221 Cr | ₹243 Cr | ₹233 Cr | ₹206 Cr | ₹174 Cr |
| Profit Before Tax | ₹-117 Cr | ₹-286 Cr | ₹-653 Cr | ₹275 Cr | ₹55 Cr |
| Profit After Tax | ₹-149 Cr | ₹-231 Cr | ₹-474 Cr | ₹244 Cr | ₹43 Cr |
| Consolidated Net Profit | ₹-71 Cr | ₹-203 Cr | ₹-460 Cr | ₹268 Cr | ₹36 Cr |
| Earnings Per Share (Rs) | ₹-7.68 | ₹-22.44 | ₹-51.25 | ₹29.93 | ₹4.06 |
| PAT Margin (%) | -2.38 | -3.70 | -8.90 | 4.45 | 0.92 |
| ROE(%) | -6.88 | -10.15 | -18.49 | 9.21 | 1.68 |
| ROCE(%) | 4.15 | -0.49 | -9.49 | 9.08 | 4.06 |
| Total Debt/Equity(x) | 1.14 | 1.27 | 1.18 | 0.76 | 0.78 |
Key Financials |
||
| Market Cap | : | ₹ 8,182.3 Cr |
| Revenue (TTM) | : | ₹ 4,632.7 Cr |
| Net Profit(TTM) | : | ₹ 358.2 Cr |
| EPS (TTM) | : | ₹ 38.8 |
| P/E (TTM) | : | 22.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| STRIDES PHARMA SCIENCE | 1.9% | 4% | -7.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.4% | -0.9% | 4.8% |
| DIVIS LABORATORIES | -0.7% | 1.6% | 50.2% |
| CIPLA | -1.7% | -1.1% | -2.3% |
| TORRENT PHARMACEUTICALS | -1.1% | 1.6% | 13.7% |
| DR REDDYS LABORATORIES | -4.3% | -8% | -4.4% |
| MANKIND PHARMA | 6.8% | 8% | 20.9% |
| ZYDUS LIFESCIENCES | -1.9% | 0.1% | -16.5% |
| LUPIN | -4.3% | -6.4% | 4.6% |
STRIDES PHARMA SCIENCE Revenues
[BOM: 532531|NSE : STAR]
| Y-o-Y | 9.83 % |
| 5 Yr CAGR | 10.15 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹4,051 Cr | 9.83 | |
| Mar2023 | ₹3,688 Cr | 20.13 | |
| Mar2022 | ₹3,070 Cr | -7.41 | |
| Mar2021 | ₹3,316 Cr | 20.49 | |
| Mar2020 | ₹2,752 Cr | - | |
STRIDES PHARMA SCIENCE Operating Profit
[BOM: 532531|NSE : STAR]
| Y-o-Y | 90.27 % |
| 5 Yr CAGR | 9.18 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹733 Cr | 90.27 | |
| Mar2023 | ₹385 Cr | Positive | |
| Mar2022 | ₹-22 Cr | Negative | |
| Mar2021 | ₹627 Cr | 21.50 | |
| Mar2020 | ₹516 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 73.21 % |
| 5 Yr CAGR | -0.88 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 18.1% | 73.21 | |
| Mar2023 | 10.45% | Positive | |
| Mar2022 | -0.7% | Negative | |
| Mar2021 | 18.9% | 0.80 | |
| Mar2020 | 18.75% | - | |
STRIDES PHARMA SCIENCE Profit After Tax
[BOM: 532531|NSE : STAR]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹-71 Cr | Negative | |
| Mar2023 | ₹-203 Cr | Negative | |
| Mar2022 | ₹-460 Cr | Negative | |
| Mar2021 | ₹268 Cr | 637.66 | |
| Mar2020 | ₹36 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | -2.38 % | Negative | |
| Mar2023 | -3.7 % | Negative | |
| Mar2022 | -8.9 % | Negative | |
| Mar2021 | 4.45 % | 383.70 | |
| Mar2020 | 0.92 % | - | |
STRIDES PHARMA SCIENCE Earnings Per Share (EPS)
[BOM: 532531|NSE : STAR]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹-7.68 | Negative | |
| Mar2023 | ₹-22 | Negative | |
| Mar2022 | ₹-51 | Negative | |
| Mar2021 | ₹30 | 637.19 | |
| Mar2020 | ₹4.06 | - | |
STRIDES PHARMA SCIENCE Return on Capital Employed (ROCE)
[BOM: 532531|NSE : STAR]
| Y-o-Y | Positive |
| 5 Yr CAGR | 0.55 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 4.15% | Positive | |
| Mar2023 | -0.49% | Negative | |
| Mar2022 | -9.49% | Negative | |
| Mar2021 | 9.08% | 123.65 | |
| Mar2020 | 4.06% | - | |
STRIDES PHARMA SCIENCE Share Price vs Sensex
| Current Share Price | : | ₹887.5 |
| Current MarketCap | : | ₹ 8,182.3 Cr |
| Updated EOD on | : | Jul 11,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| STRIDES PHARMA SCIENCE | 1.9% |
4% |
-7.9% |
| SENSEX | -1.1% |
-0% |
3.2% |
STRIDES PHARMA SCIENCE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE SMALLCAP | -0.6% | 0.4% | 0.8% |
| BSE HEALTHCARE | -1.3% | 0.7% | 16.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | -0.3% | -0.2% | 1% |
| NIFTY MIDSMALL HEALTHCARE | -1.1% | 3% | 19.8% |
| NIFTY TOTAL MARKET | -1.2% | -0.2% | 1.4% |
You may also like the below Video Courses
FAQ about STRIDES PHARMA SCIENCE Financials
How the annual revenues of STRIDES PHARMA SCIENCE have changed ?
The Revenues of STRIDES PHARMA SCIENCE have increased by 9.83% YoY .
How the Earnings per Share (EPS) of STRIDES PHARMA SCIENCE have changed?
The Earnings Per Share (EPS) of STRIDES PHARMA SCIENCE has decreased by Negative YoY .
Check out Intrinsic Value of Peers of STRIDES PHARMA SCIENCE
Compare Stock Analytics of Peers of STRIDES PHARMA SCIENCE
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
